Literature DB >> 18547996

Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease.

Sai Ram Keithi-Reddy1, Francesco Addabbo, Tejas V Patel, Bharati V Mittal, Michael S Goligorsky, Ajay K Singh.   

Abstract

Inflammatory cytokines are important predictors of cardiovascular mortality especially in patients with chronic kidney disease. Here we explored the relationship of anemia and epoetin treatment to inflammatory cytokine levels in patients with chronic kidney disease. One hundred non-dialysis patients with chronic kidney disease over 18 years of age were evenly split into anemic and non-anemic cohorts. Of the 50 anemic patients, 23 were receiving erythropoiesis stimulating agents treatments. Levels of tumor necrosis factor (TNF)-alpha were found to be significantly higher and serum albumin was significantly lower with trends towards higher interleukin (IL)-6 and IL-8 in anemic compared to non-anemic patients. Further analysis by multiple logistic regression found that anemic patients treated with erythropoiesis stimulating agents had significantly higher odds for the upper two quartiles for IL-6, IL-8 and TNF-alpha compared to non-anemic patients. Our study found that the anemia of chronic kidney disease was associated with up regulation of TNF-alpha, and possibly IL-6 and IL-8 along with increased levels of these proinflammatory cytokines in patients treated with epoetin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547996      PMCID: PMC2739585          DOI: 10.1038/ki.2008.245

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  49 in total

Review 1.  Anemia of chronic disease.

Authors:  Guenter Weiss; Lawrence T Goodnough
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 2.  Endothelial function and inflammation in coronary artery disease.

Authors:  D Tousoulis; M Charakida; C Stefanadis
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

3.  Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy.

Authors:  Sundararaman Swaminathan; Iftikhar Ahmed; James T McCarthy; Robert C Albright; Mark R Pittelkow; Noel M Caplice; Matthew D Griffin; Nelson Leung
Journal:  Ann Intern Med       Date:  2006-08-01       Impact factor: 25.391

4.  Proinflammatory state and circulating erythropoietin in persons with and without anemia.

Authors:  Luigi Ferrucci; Jack M Guralnik; Richard C Woodman; Stefania Bandinelli; Fulvio Lauretani; Anna Maria Corsi; Paulo H M Chaves; William B Ershler; Dan L Longo
Journal:  Am J Med       Date:  2005-11       Impact factor: 4.965

5.  Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia.

Authors:  Antonio Macciò; Clelia Madeddu; Daniela Massa; Maria C Mudu; Maria R Lusso; Giulia Gramignano; Roberto Serpe; Gian Benedetto Melis; Giovanni Mantovani
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

6.  Biomarkers of inflammation and progression of chronic kidney disease.

Authors:  Marcello Tonelli; Frank Sacks; Marc Pfeffer; Gian S Jhangri; Gary Curhan
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

7.  Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis.

Authors:  P V Voulgari; G Kolios; G K Papadopoulos; A Katsaraki; K Seferiadis; A A Drosos
Journal:  Clin Immunol       Date:  1999-08       Impact factor: 3.969

Review 8.  IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly.

Authors:  Peter Stenvinkel; Markus Ketteler; Richard J Johnson; Bengt Lindholm; Roberto Pecoits-Filho; Miguel Riella; Olof Heimbürger; Tommy Cederholm; Matthias Girndt
Journal:  Kidney Int       Date:  2005-04       Impact factor: 10.612

9.  Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts.

Authors:  G Lonnemann; L Shapiro; G Engler-Blum; G A Müller; K M Koch; C A Dinarello
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

10.  Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease.

Authors:  Anjali Desai; Ying Zhao; Heather A Lankford; Jeffrey S Warren
Journal:  Lab Invest       Date:  2006-04       Impact factor: 5.662

View more
  14 in total

1.  Correction of postkidney transplant anemia reduces progression of allograft nephropathy.

Authors:  Gabriel Choukroun; Nassim Kamar; Bertrand Dussol; Isabelle Etienne; Elisabeth Cassuto-Viguier; Olivier Toupance; François Glowacki; Bruno Moulin; Yvon Lebranchu; Guy Touchard; Maïté Jaureguy; Nicolas Pallet; Yannick Le Meur; Lionel Rostaing; Frank Martinez
Journal:  J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 10.121

2.  Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?

Authors:  Luca De Nicola; Francesco Locatelli; Giuseppe Conte; Roberto Minutolo
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

3.  Clinical factors and the decision to transfuse chronic dialysis patients.

Authors:  Cynthia B Whitman; Sanatan Shreay; Matthew Gitlin; Martijn G H van Oijen; Brennan M R Spiegel
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 8.237

4.  Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors.

Authors:  Jula K Inrig; Suzanne K Bryskin; Uptal D Patel; Murat Arcasoy; Lynda A Szczech
Journal:  BMC Nephrol       Date:  2011-12-12       Impact factor: 2.388

5.  Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.

Authors:  Eleonora Riccio; Massimo Sabbatini; Dario Bruzzese; Ivana Capuano; Silvia Migliaccio; Michele Andreucci; Antonio Pisani
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

6.  Effect of erythropoietin on primed leucocyte expression profile.

Authors:  Mirko Pesce; Paolo Felaco; Sara Franceschelli; Lorenza Speranza; Alfredo Grilli; Maria Anna De Lutiis; Alessio Ferrone; Vittorio Sirolli; Mario Bonomini; Mario Felaco; Antonia Patruno
Journal:  Open Biol       Date:  2014-06       Impact factor: 6.411

7.  Frequency of TGF- β and IFN- γ genotype as risk factors for acute kidney injury and death in intensive care unit patients.

Authors:  Caren Cristina Grabulosa; Marcelo Costa Batista; Miguel Cendoroglo; Beata Marie Redublo Quinto; Roberto Narciso; Julio Cesar Monte; Marcelino Durão; Luiz Vicente Rizzo; Oscar Fernando Pavão Santos; Maria Aparecida Dalboni
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

8.  Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.

Authors:  Motoko Tanaka; Kazuki Yoshida; Shingo Fukuma; Kazuko Ito; Kazutaka Matsushita; Masafumi Fukagawa; Shunichi Fukuhara; Tadao Akizawa
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

9.  Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.

Authors:  Eliyahu V Khankin; Walter P Mutter; Hector Tamez; Hai-Tao Yuan; S Ananth Karumanchi; Ravi Thadhani
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

10.  A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis.

Authors:  Ha-Young Na; Yong-Kyu Lee; Sug-Kyun Shin; Dong-Ho Yang; Woong Cheon; Jung-Hwan Park; Jong-Ho Lee; Jong-Oh Song; Young-Il Jo
Journal:  Kidney Res Clin Pract       Date:  2014-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.